Format

Send to

Choose Destination
Br J Haematol. 2015 Apr;169(1):77-80. doi: 10.1111/bjh.13262. Epub 2014 Dec 15.

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.

Author information

1
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Abstract

Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

KEYWORDS:

momelotinib; myelofibrosis; myeloproliferative; neuropathy

PMID:
25511866
DOI:
10.1111/bjh.13262
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center